inspection – Page 273

Process change implemented without QA approval during routine manufacturing – regulatory impact assessment case study

Assessment of a Manufacturing Process Change Implemented Without QA Approval In the highly regulated pharmaceutical industry, adherence to established protocols is paramount. This case study discusses a significant deviation where…

Deviation closed without effectiveness check during changeover – FDA inspection observation breakdown

Case Study: Addressing a Deviation Closed Without Effectiveness Check During Changeover Understanding and resolving manufacturing deviations is critical in pharmaceutical production. This case study focuses on a specific instance where…

Deviation closed without effectiveness check during changeover – FDA inspection observation breakdown

Case Study: Addressing a Deviation Closed Without Effectiveness Check During Changeover In the regulated environment of pharmaceutical manufacturing, adherence to Good Manufacturing Practices (GMP) is vital. However, deviations can occur,…

Batch executed with expired SOP during commercial campaign – root cause analysis failure explained

“`html Root Cause Analysis in Pharmaceutical Manufacturing: Addressing the Execution of a Batch with Expired SOP In a recent real-world scenario, a pharmaceutical manufacturer discovered that a batch of product…

Batch executed with expired SOP during commercial campaign – root cause analysis failure explained

Root Cause Analysis of a Batch Executed with Expired SOP During Commercial Campaign In the highly regulated pharmaceutical industry, adherence to Standard Operating Procedures (SOPs) is critical for ensuring product…

Unapproved process parameter change during commercial campaign – FDA inspection observation breakdown

Breakdown of FDA Inspection Observations Following an Unapproved Process Parameter Change During Commercial Campaign In the highly regulated environment of pharmaceutical manufacturing, adhering to established process parameters is critical. A…

Unapproved process parameter change during commercial campaign – FDA inspection observation breakdown

Analysis of an Unapproved Change in Process Parameters During a Commercial Campaign In the landscape of pharmaceutical manufacturing, maintaining compliance with Good Manufacturing Practices (GMP) is crucial to ensure product…

Unapproved process parameter change during inspection preparation – CAPA ineffectiveness identified

Analysis of an Unapproved Process Parameter Change in Inspection Readiness In a recent scenario at a biopharmaceutical manufacturing facility, an unapproved change to a process parameter was discovered during preparations…

Unapproved process parameter change during inspection preparation – CAPA ineffectiveness identified

Exploring Unapproved Process Parameter Changes During Inspection Readiness and CAPA Outcomes A large pharmaceutical manufacturing facility recently faced a significant challenge leading to substantial operational disruptions and heightened scrutiny during…

Unplanned hold time extension during inspection preparation – root cause analysis failure explained

“`html Understanding Unplanned Delays in Inspection Prep: A Root Cause Case Study In a recent scenario at a biotech manufacturing facility, an unplanned hold time extension was observed during the…

Unplanned hold time extension during inspection preparation – root cause analysis failure explained

Investigation into Unplanned Hold Time Extensions During Inspection Preparations In the highly regulated pharmaceutical industry, any deviation from established protocols can lead to significant regulatory scrutiny. This case study details…

Equipment used without release during routine manufacturing – regulatory impact assessment case study

Investigating Equipment Utilization Without Release in Routine Pharmaceutical Manufacturing In the ever-evolving pharmaceutical industry, ensuring compliance with regulatory requirements is paramount. A critical issue arose when a major pharmaceutical company…